结直肠癌患者化疗后肝功能异常的分析  

Analysis of liver dysfunction in patients with chemotherapeutic treatment for colorectal cancer

作　　者：陈喆[1] 贾贝[1] 乔涌起[1] 戴媛媛[1] 李国辉[1] 

机构地区：[1]中国医学科学院肿瘤医院药剂科,北京100021

出　　处：《临床药物治疗杂志》2015年第1期53-57,共5页Clinical Medication Journal

摘　　要：目的:分析结直肠癌患者化疗后肝功能异常的特点和易感因素。方法:回顾性分析2013年6月—2014年5月中国医学科学院肿瘤医院内科住院治疗的结直肠癌患者化疗后肝功能异常的特点,对化疗后肝功能异常与临床参数进行相关因素分析。结果:580例患者共接受了3 033周期的化疗,平均5.23周期/例,有170例在化疗过程中出现不同程度的肝功能异常,占29.3%。有140例为1度肝损伤,23例为2度损伤,6例为3度损伤,1例为4度损伤。相关因素分析显示肝功能异常与化疗总周期数、治疗类型及化疗药物相关(P<0.05)。结论:化疗所致肝功能异常的易感因素为化疗总周期数、治疗类型及化疗药物。化疗后肝功能异常的程度多为1度,化疗所致的肝损伤以肝细胞型为主。Objective： To analyze the characteristics and risk factors of liver dysfunction after chemotherapy in patients with colorectal cancer. Methods： Characteristics of liver dysfunction in patients with colorectal cancer after chemotherapy who admitted to Cancer Institute ＆ Hospital of Chinese Academy of Medical Sciences between June 2013 and May 2014 were retrospectively analyzed. Chi-square test was employed for univariate analysis on correlation between chemotherapy-induced liver dysfunction and clinical pathological parameters. Results： 580 patients received a total of 3 033 cycles of chemotherapy （5.23cycles/patient）. There were 170 cases with chemotherapy induced different degree of liver dysfunction, the incidence rate was 29.3%.There were 140 cases in Grade 1 liver dysfunction, 23 cases in Grade 2, 6 cases in Grade 3 and 1 case in Grade 4. Coneluslon： Predisposing factors for chemotherapyinduced liver dysfunction included the cycles of chemotherapy, the type of chemotherapy, and the chemotherapy regimens. Most common type of chemotherapy-induced liver dysfunction was hepatocellular necrosis and most of the disorder was of Gradel abnormality.

关 键 词：结直肠癌 化疗 肝功能异常 

分 类 号：R735.3[医药卫生—肿瘤]